Can not agree with your statement that mpl hasn't missed a target, the main endpoint for the phase 2b canine trial was to reach 18 out of 46 dogs showing the required improvement, it failed to reach this.
That is a false statemnentt. Nobody ever said this was going to be a cure for the ultra-aggressive B cell lymphoma in dogs but it did, on average, measurably extend their lives and the point was that it was an alternative to chemo.
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-1137
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
-0.010(5.41%) |
Mkt cap ! $69.28M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 18.5¢ | 17.5¢ | $58.74K | 325.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 270003 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 116651 | 3 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
18.0¢ |
Change
-0.010 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 18.0¢ | 18.0¢ | 17.5¢ | 141605 | ||
| Last updated 15.28pm 21/05/2024 ? | |||||
| PAA (ASX) Chart |